recommendations for the clinical management of hepatitis c in iran: a consensus-based national guideline

conclusions affordable new hcv treatment regimens are available in iran, providing an opportunity for hcv elimination. recommendations provided in this current national guideline can facilitate evidence-based management of hcv infection. results pegylated interferon alpha (pegifn), ribavirin (rbv), sofosbuvir (sof), ledipasvir (ldv) and daclatasvir (dcv) are currently available in iran. pre-treatment assessments include hcv rna level, hcv genotype and resistance testing, assessment of liver fibrosis, and underlying diseases. in hcv genotype 1 and 4, dcv/sof and ldv/sof are recommended. in hcv genotype 2, sof plus rbv and in hcv genotype 3, dcv/sof is recommended. additional care for underlying diseases should be considered. evidence acquisition the recommendations of this guideline are based on international and national scientific evidences and consensus-based expert opinion. scientific evidences were collected through a systematic review of studies that evaluated efficacy and safety of daa regimens, using pubmed, scopus and web of science. expert opinion was based on the consensus of iran hepatitis scientific board (ihsb) in the 3rd national consensus on management of hepatitis c in iran, held on 22nd of july 2016. context hepatitis c virus (hcv) infection is a major public health issue worldwide, including iran. the new direct-acting antiviral agents (daas) with high efficacy have changed the landscape of hcv treatment. this guideline provides updated recommendations for clinical management of hcv infection in iran.